Key factors
symREXN
exchUS
MCap2028.65K
Beta0.973
EPS-4.83
Div date0000-00-00
Yesterday
symREXN
exchUS
close6.0
50 Day MA7.198
200 Day MA9.508
Target Price 3.0
Market Cap Mln2.028
Share statistics
Shares Outstanding4483.2K
Shares Float4010.14K
Percent Institutions8.326
PercentInsiders0.222
SharesShort13595
Short Ratio0.05
Shares Short Prior Month2963.0
Short Percent0.079
Revenue TTM 1150.0K
Revenue Per Share TTM 0.282
EBITDA-16.5M
Diluted Eps TTM-2.65
earning
Operating Margin TTM -5.58
Earnings Share -4.83
Dividend
Dividend Date0000-00-00
Last Split Date 2019-04-12
Last Split Factor1:12
business
Enterprise Value Ebitda 0.021
Enterprise Value Revenue0.117
Book Value /share 2.925
Price Book MRQ 1.420
Price Sales TTM 6.413
ReturnOnAssetsTTM -0.33
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Gic Sector Health Care
Gic Sub Industry Biotechnology
IndustryBiotechnology
SectorHealthcare
ISIN US7616403090
CIK 1228627
Code REXN
CUSIP 22003E100
CountryISO US
Currency CodeUSD
Currency Name US Dollar
Exchange NASDAQ
Currency Symbol $
Type Common Stock
UpdatedAt 2023-12-12
is Delisted 1
Delisted Date 2020-11-06
Home Category Domestic
Fiscal Year End December
Full Time Employees5.0
IPODate 2005-05-23
MostRecent Quarter2020-09-30
Contact
NameRexahn Pharmaceuticals Inc
Address15245 Shady Grove Road, Rockville, MD, United States, 20850
Country NameUSA
Phone240 268 5300
Web URLwww.rexahn.com
Logo URL/img/logos/US/REXN.png
As of November 5, 2020, Rexahn Pharmaceuticals, Inc. was acquired by Ocuphire Pharma, Inc., in a reverse merger transaction. Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; and BioSense Global LLC. The company is headquartered in Rockville, Maryland.